All In Biotech

Drug Trial Radar · NCT00589693

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia

Last checked: Nov 20, 2026Latest source record: Dec 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

274

Actual

Start

Apr 2008

Primary completion

Jun 2011

Study completion Jun 2011

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.

Conditions

  • Ventilator-Associated Pneumonia

Interventions

  • DoripenemDrug

    Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.

  • Imipenem-CilastatinDrug

    Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.

  • PlaceboDrug

    Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure Rate at the End-of-treatment (EOT) VisitTime frame: End-of-treatment (Day 10 or Day 11)

Locations

100 sites in 21 countries. Site status is shown where the registry gives one.

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Newark, Delaware

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Jacksonville, Florida

  • Site not named

    Moline, Illinois

  • Site not named

    Hazard, Kentucky

  • Site not named

    Biddeford, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Detroit, Michigan

  • Site not named

    Butte, Montana

  • Site not named

    Buffalo, New York

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Entre Ríos, Argentina

  • Site not named

    Monte Grande, Argentina

  • Site not named

    Rio Negro, Argentina

  • Site not named

    Rosario, Argentina

  • Site not named

    Adelaide, Australia

  • Site not named

    Box Hill, Australia

  • Site not named

    Clayton, Australia

  • Site not named

    Melbourne, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Belo Horizonte, Brazil

  • Site not named

    Curitiba, Brazil

  • Site not named

    Fortaleza, Brazil

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Santo André, Brazil

  • Site not named

    São José do Rio Preto, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Ottawa, Ontario, Canada

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.